State and Local Policies Regarding IDUs' Access to Sterile Syringes December 2005

Similar documents
Syringe Exchange Programs December 2005

State Approaches to Expanded Access to Sterile Syringes Through Pharmacies

Overview of Evidence for Sterile Syringe Access. Hilary McQuie Western Director Harm Reduction Coalition

What s The Point? The unique role of pharmacists in HIV/HCV. prevention efforts BAY AREA AND NORTH COAST AREA APRIL 30, 2016

who use drugs in order to assist them in reducing harm while in the cycle of addiction

Overview of Syringe Exchange Programs. New York City Police Academy November 24, 2004

Syringe Exchange Programs: Getting Started

September 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201

PRODUCTS: All products containing ephedrine (EPH) and pseudoephedrine (PSE). (IC )

The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015

Australian Injecting and Illicit Drug Users League. Policy Position Paper 8 Retractable Syringes

Working with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.

Training Program Online Resources for the Basic I IDU HIV PREVENTION HIV PREVENTION

(Reprinted with amendments adopted on April 26, 2011) FIRST REPRINT S.B. 335 MARCH 21, Referred to Committee on Health and Human Services

Narrative Science-based literature on Syringe Exchange Programs (SEPs)

1 HB By Representative Williams (JD) 4 RFD: Health. 5 First Read: 09-JAN-18 6 PFD: 11/28/2017. Page 0

MEDICAL MARIJUANA USE

Drug Consumption Rooms: Legal barriers or just an excuse? Kirstie Douse Head of Legal Services Solicitor Advocate

Amanda Archer, BS, MPH

Advocating for Syringe Exchange Programs

NEEDLES/SYRINGES TO INJECTION DRUG USERS BEFORE EXPANDING SYRINGE ACCESS

Ethics of Over the Counter Syringe Sales To Injection Drug Users. Stephanie J. Andrews December 2006

Guidelines For Services Providing Injecting Equipment

Infectious Disease The Public Health Response

Needle Exchange Program: Considerations for Criminal Justice. NEEDLE EXCHANGE PROGRAMS: Considerations for Criminal Justice

Background. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)

HIV, drugs and the legal environment

Harm Reduction and Syringe Exchange Programs in the City and County of Los Angeles

Temple University of the Commonwealth System of Higher Education Beasley School of Law. Memorandum

A. The unlawful possession, use, distribution, manufacture, or dispensing of illicit drugs on EVMS property or at an EVMS off-campus activity.

SENATE, No STATE OF NEW JERSEY. 218th LEGISLATURE INTRODUCED FEBRUARY 5, 2018

Maine Survey Results

DELTA SIGMA THETA SORORITY, INC. A Service Sorority

SYRINGE PROGRAMS AND HARM REDUCTION

A Legal Look at Medical Marijuana. John J. Clifford, Esq. Clifford and Kenny, LLP 171 Rockland Street Hanover, MA 02339

Investigation Timeline

Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary

Articles. Lethal Injections: The Law, Science, and Politics of Syringe Access for Injection Drug Users* By ScoTr BuRms,**

Provider Education & Utilization Initiatives Alliance of States with PMPs East Regional Meeting

ISSUE BRIEF. Preventing HIV and Hepatitis C Among People Who Inject Drugs: Public Funding for Syringe Services Programs Makes the Difference

Temple University of the Commonwealth System of Higher Education Beasley School of Law. Project on Harm Reduction in the Health Care System

Good Samaritan and Naloxone Bill Status Report Carryover 2015 and Special Sessions

Implementing the 2017 President s Challenge: Primary, Secondary & Tertiary Prevention of Addiction & Substance Misuse

Maine s Medical Marijuana Law. 40 th Annual ASMAC Fall Conference Ritz Carlton Lake Tahoe October 26, 2014

Prescription Drug Monitoring Program (PDMP) Delaware. Information contained in this presentation is accurate as of November 2017

Prescription Drug Monitoring Program (PDMP)

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis

Hepatitis C in Massachusetts Epidemiology and Public Health Response

Targeted Outreach & Other Strategies for Increasing HCV Testing

Syringe Exchange Research Update Harm Reduction Coalition August 2008

NEOMED ACADEMIC POLICY

HIV AND PEOPLE WHO INJECT DRUGS

SUBJECT: Cannabis legislation and implications for the City of Burlington

Policy \ \ Medical (Palliative) Use of Marijuana

Marijuana Legalization Update

Temple University of the Commonwealth System of Higher Education Beasley School of Law. Project on Harm Reduction in the Health Care System

High Impact Prevention for People Who Inject Drugs. June 30, 2015

A Drug Policy for the 21st Century

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health

RISE Needle Exchange Program

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

Historical Perspectives

Barriers to Access: Exploring Factors that Inhibit Use of. Over-The-Counter Pharmacy Sales. as a Source of Sterile Needles and Syringes

Barriers, Concerns, and Recommended Course of Action for Expedited Partner Therapy for the Treatment of Gonorrhea and Chlamydia

Policy / Drug and Alcohol-Free Workshops

Home Model Legislation Public Safety and Elections. Methamphetamine Reduction Act

Substance use and misuse

Workplace Drug and Alcohol Policy

OPIOID OVERDOSE EPIDEMIC: What Healthcare Providers Need to Know

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and

WA DRUG ABUSE STRATEGY OFFICE

Coversheet: Medicinal cannabis: 100 day action

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1

SYRINGE SERVICES PROGRAMS IN INDIANA

The Epidemics of Injecting Drug Use and Blood- Borne Disease: A Public Health Perspective

Drug Free Workplace and Employee Drug and Alcohol Testing

Medical marijuana vs. workplace policy

Evidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April 1998

Prescription Drug Monitoring Programs and Other State-Level Strategies

PH52. Audit tool for the implementation of. NICE public health guidance 52 Needle and syringe programmes

MEMORANDUM INTRODUCTION. DATE: July 28, 2016; Revised August 3, 2016 TO:

Smoke and Mirrors: Navigating Medical Marijuana in the Workplace

Hepatitis C Best Practice Guidelines For Local Health Departments

Criminal Justice (Psychoactive Substances) Bill Regulatory Impact Analysis

Presenters. Session Objectives. Session Overview. Cluster Investigations in Rural Wisconsin

France: Millions of medicines seized in largest INTERPOL operation against illicit online pharmacies

The sharing of needles and syringes (hereafter syringes )

WINDBER AREA SCHOOL DISTRICT

Prison needle exchange: Review of the evidence


Local Legislative Approval and Program Certification

Strategies for Federal Agencies

Shannon Whitman Program Administrator Advancing Use of the MN PMP

THE STATE OF THE MEDICAL MARIJUANA MARKETS 2011

HHS Public Access Author manuscript Int J Drug Policy. Author manuscript; available in PMC 2016 November 01.

SUNRISE, FLORIDA ORDINANCE NO.

SACI ALCOHOL AND DRUG ABUSE PREVENTION POLICY

Northern Alberta preventing HIV transmission to babies

Public Health Federal Funding Request to Address the Opioid Epidemic

Transcription:

State and Local Policies Regarding IDUs' Access to Sterile Syringes December 2005 In many cities and states, laws and regulations make possession of syringes a crime and limit IDUs' ability to legally purchase syringes. As a result, IDUs who continue to inject often cannot follow prevention advice to use a sterile syringe for every injection. Several states also have restricted the funding or operation of syringe exchange programs (SEPs). On the federal level, funding to carry out any program of distributing sterile needles or syringes to IDUs has been prohibited by Congress since 1988. As of 2004, injection drug use accounted for about one-fifth of all HIV infections and most hepatitis C infections in the United States.(1,2) Injection drug users (IDUs) become infected and transmit the viruses to others through sharing contaminated syringes and other drug injection equipment and through high-risk sexual behaviors. Women who become infected with HIV through sharing needles or having sex with an infected IDU can also transmit the virus to their babies before or during birth or through breastfeeding. To effectively reduce the transmission of HIV and other blood-borne infections, programs must consider a comprehensive approach to working with IDUs. Such an approach incorporates a range of pragmatic strategies that address both drug use and sexual risk behaviors. One of the most important of these strategies is ensuring that IDUs who cannot or will not stop injecting drugs have access to sterile syringes. (See the related fact sheet Access to Sterile Syringes.) This strategy supports the "one-time-only use of sterile syringes" recommendation of several institutions and governmental bodies, including the U.S. Public Health Service.(3) IDUs share syringes and injection equipment for multiple reasons, but primarily because of legal and regulatory barriers limiting access to sterile syringes and laws making possession of syringes a crime. What Laws and Regulations Affect Illegal Injection Drug Use? Several interrelated laws and regulations restrict IDUs ability or willingness to obtain and possess syringes:(4) Drug paraphernalia laws. These laws establish criminal penalties for the manufacture, sale, distribution, possession, or advertisement of any item used to produce and consume illegal drugs, including syringes. In 2002, 47 states, the District of Columbia, and the Virgin Islands had drug paraphernalia laws. Syringe prescription laws. These laws prohibit dispensing or possessing syringes without a valid medical prescription. In 2002, eight states and one territory had syringe prescription laws. In 2000, an analysis of state laws

showed that physician prescription of sterile syringes to IDUs is legal in 46 states; in two other states physicians have a "reasonable claim to legality."(5) (See the related fact sheet, Physician Prescription of Sterile Syringes to Injection Drug Users.) Pharmacy regulations and practice guidelines. As part of their oversight responsibilities, state boards of pharmacy develop and enforce regulations and guidelines that cover many aspects of syringe sales, including display, advertising, record keeping, log books, customer identification, and assessments of customers probable use. Twenty-three states have such regulations and guidelines. (See the related fact sheet Pharmacy Sales of Sterile Syringes.) Restrictions on syringe exchange programs. In some states, syringe prescription laws and drug paraphernalia laws effectively restrict the ability of syringe exchange programs (SEPs) to operate unless they are specifically exempted from the laws. (See the related fact sheet Syringe Exchange Programs.) These laws and regulations are structural barriers that create a situation in which IDUs who continue to inject are advised to use only sterile syringes, but at the same time, are often prevented from carrying out this advice. Because holding on to or carrying syringes puts IDUs at risk of police searches, arrest, and criminal prosecution, they can be reluctant to participate in sterile syringe access or risk reduction initiatives such as syringe exchange or safe disposal programs.(6) (See the related fact sheet Syringe Disposal.) This environment may increase transmission risks because IDUs who are concerned about being arrested for obtaining or carrying syringes are more likely than other IDUs to share syringes and injection supplies.(7) What Has Been Done to Address Structural Issues? Several states have undertaken initiatives to change syringe laws and regulations: In 1992, Connecticut partially repealed its laws and regulations that limited pharmacy sales of syringes and made possession of syringes a crime. This allowed pharmacy sales of up to 10 syringes without a prescription and legalized the possession of up to 10 drug-free syringes.(8,9) In 1993, Maine changed its laws to allow anyone aged 18 or older to purchase from a pharmacy any quantity of syringes.(10) In January 1997, the state legislature adopted rules to permit legal syringe exchange and to remove the criminal penalties for possessing 10 or fewer syringes. In 1997, as part of a comprehensive HIV prevention bill, the Minnesota legislature changed its laws to allow pharmacies to sell up to 10 syringes without a prescription and permit individuals to legally possess up to 10 unused syringes at a time. In 2000, New York State changed existing syringe prescription and drug paraphernalia laws to allow persons 18 years and older to purchase and/or possess 10 or fewer syringes without a prescription and without being liable for arrest.(11) Other states have developed specific strategies to allow the legal operation of SEPs. For example, five states (Hawaii, Maryland, Massachusetts, New York,

and Rhode Island) and the District of Columbia have given their health departments the power to establish SEPs and to exempt them from drug paraphernalia laws. Three states (Connecticut, Massachusetts, and Rhode Island) have specifically exempted SEPs from their prescription laws. In some municipalities, public officials have sought legal authority to conduct SEPs by declaring a local state of public health emergency. In 1999, the American Medical Association, American Pharmaceutical Association, and other organizations called for state-level review of syringe laws and regulations.(12) Some states have reported a benefical public health impact. For example, after the partial repeal of syringe laws in Connecticut, pharmacies in that state began to sell nonprescription syringes.(9,13) As a result, more IDUs purchased syringes from pharmacies, syringe sharing decreased, and police reported fewer needle stick injuries.(8) Further, there is no evidence that ensuring access to sterile syringes increases the number of persons who inject or the number of injections.(14,15) Policy Considerations At the community level, both public health and law enforcement have strong interests that must be supported. Public health seeks to reduce drug use and bloodborne transmission of disease by helping individuals enter substance abuse treatment and change their risky sexual and drug-use behaviors. Law enforcement has an equally strong stake in preventing and punishing the distribution and sale of illicit drugs. State and local initiatives aimed at legal and regulatory reform need to find ways to strike a middle ground so that the interests of both are served. Such efforts include: Supporting initiatives to expand and improve collaboration and understanding between public health and law enforcement. Encouraging review of the public health impact of current syringe prescription and drug paraphernalia laws and pharmacy regulations on the availability of sterile syringes to those IDUs who are unable or unwilling to stop injecting. Educating policy makers about the facts of injection-related transmission of blood-borne pathogens and the public health benefits of providing access to sterile syringes as part of a comprehensive public health approach. Carrying out initiatives to educate and inform community leaders, physicians, pharmacists, law enforcement, and the public about the importance of access to sterile syringes to IDUs as one component of a comprehensive approach to stopping drug use and reducing transmission of blood-borne diseases. For More Information Read A Comprehensive Approach: Preventing Blood-Borne Infections Among Injection Drug Users, which provides extensive background information on HIV and viral hepatitis infection in IDUs and on the legal, social, and policy environment. It also describes strategies and principles for addressing these issues.

Sources 1. Glynn M, Rhodes P. Estimated HIV prevalence in the United States at the end of 2003. 2005 National HIV Prevention Conference; June 12 15, 2005. Atlanta, GA. Abstract T1-B1101. 2. Centers for Disease Control and Prevention (CDC). Hepatitis C fact sheet. Accessed December 22, 2005 from http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm. 3. Centers for Disease Control and Prevention, Health Resources and Services Administration, National Institute on Drug Abuse and Substance Abuse and Mental Health Services Administration. HIV prevention bulletin: Medical advice for persons who inject illicit drugs. May 9, 1997. 4. Gostin LO. The legal environment impeding access to sterile syringes and needles: The conflict between law enforcement and public health. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S60-S70. 5. Burris S, Lurie P, Abrahamson D, Rich ID. Physician prescribing of sterile injection equipment to prevent HIV infection: time for action. Annals of Internal Medicine 2000; 133(3): 218-226. 6. Springer KW, Sterk CE, Jones TS, Friedman L. Syringe disposal options for injection drug users: A community-based perspective. Substance Use and Misuse 1999;34(13):1917-1934. 7. Bluthenthal RN, Kral AH, Erringer EA, Edlin BR. Drug paraphernalia laws and injection-related infectious disease risk among drug injectors. Journal of Drug Issues 1999;29(1):1-16. 8. Groseclose SL, Weinstein B, Jones TS, Valleroy LA, Fehrs LJ, Kassler WJ. Impact of increased legal access to needles and syringes on the practices of injecting-drug users and police officers Connecticut, 1992-93. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;10:82-89. 9. Valleroy LA, Weinstein B, Jones TS, Groseclose SL, Rolfs RT, Kassler WJ. Impact of increased legal access to needles and syringes on community pharmacies needle and syringe sales Connecticut, 1992-1993. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1995;10(1):73-81. 10. Beckett GA, Galena R, Shields D, Mills DA. Maine removed criminal penalties for syringe possession in 1997 after allowing sale of syringes without a prescription in 1993. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S145-S146. 11. Plevin L. State bill allows sale of syringes. Newsday. May 6, 2000. Page A03.

12. National Alliance of State and Territorial AIDS Directors. HIV prevention and access to sterile syringes. Joint letter issued by the American Medical Association, American Pharmaceutical Association, Association of State and Territorial Health Officials, National Association of Boards of Pharmacy, National Alliance of State and Territorial AIDS Directors. October 1999. 13. Wright-De Agüero L, Weinstein B, Jones TS, Miles J. Impact of the change in Connecticut syringe prescription laws on pharmacy sales and pharmacy managers practices. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998;18(Suppl 1):S102-S110. 14. Normand J, Vlahov D, Moses LE, eds. Preventing HIV transmission: the role of sterile needles and bleach. Washington (DC): National Academy Press, 1995. 15. Needle RH, Coyle SL, Normand J, Lambert E, Cesari H. HIV prevention with drugusing populations current status and future prospects: introduction and overview. Public Health Reports 1998;113(Suppl 1):4-18.